NCT06845319View on ClinicalTrials.gov

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

October 20, 2027

Study Completion Date

October 20, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Carboplatin

Carboplatin target AUC 5 every 3 weeks for 12-18 weeks OR target AUC 1.5 every week for 12-18 weeks (per investigator's choice).

DRUG

Paclitaxel

80mg/m2 weekly

DRUG

Pembrolizumab

200 mg every 3 weeks for 4 cycles

Trial Locations (1)

29425

RECRUITING

Medical University of South Carolina, Charleston

All Listed Sponsors
lead

Medical University of South Carolina

OTHER